Institutional investors hold a majority ownership of PGNX through the 85.72% of the outstanding shares that they control. This interest is also higher than at almost any other company in the Biotechnology industry. Last, during the quarter ended September 2017, these large investors purchased a net $3.3 million shares.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
ARDSLEY ADVISORY PARTNERS Bought 1.4 Million shares of Progenics Pharmaceuticals...
BLACKROCK FUND ADVISORS Bought 221.1 Thousand shares of Progenics Pharmaceuticals...